- Previous Close
16.18 - Open
16.19 - Bid 16.31 x 300
- Ask 16.35 x 700
- Day's Range
15.91 - 16.63 - 52 Week Range
13.93 - 42.08 - Volume
1,372,462 - Avg. Volume
2,071,452 - Market Cap (intraday)
1.474B - Beta (5Y Monthly) 1.44
- PE Ratio (TTM)
25.92 - EPS (TTM)
0.63 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.71
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
www.progyny.com563
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PGNY
View More
Performance Overview: PGNY
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PGNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PGNY
View MoreValuation Measures
Market Cap
1.47B
Enterprise Value
1.23B
Trailing P/E
25.92
Forward P/E
10.14
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.44
Price/Book (mrq)
3.23
Enterprise Value/Revenue
1.08
Enterprise Value/EBITDA
16.64
Financial Highlights
Profitability and Income Statement
Profit Margin
5.54%
Return on Assets (ttm)
6.45%
Return on Equity (ttm)
13.56%
Revenue (ttm)
1.13B
Net Income Avi to Common (ttm)
62.75M
Diluted EPS (ttm)
0.63
Balance Sheet and Cash Flow
Total Cash (mrq)
262.19M
Total Debt/Equity (mrq)
4.35%
Levered Free Cash Flow (ttm)
156.67M
Research Analysis: PGNY
View MoreCompany Insights: PGNY
PGNY does not have Company Insights
Research Reports: PGNY
View MoreLowering target price to $13.00
PROGYNY INC has an Investment Rating of SELL; a target price of $13.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $26.00
PROGYNY INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $24.00
PROGYNY INC has an Investment Rating of HOLD; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $23.00
PROGYNY INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target